Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Exclusive Breastfeeding and the Risk of Postpartum Relapses in Women with Multiple Sclerosis
Arch Neurol 66:958-963, Langer-Gould,A.,et al, 2009
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Recent Use of Oral Contraceptives and the Risk of Multiple Sclerosis
Arch Neurol 62:1362-1365, Alonso,A.,et al, 2005
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Breast Feeding and Multiple Sclerosis
BMJ 308:1411-1412, Pisacane,A.,et al, 1994
Risk of Multiple Sclerosis Exacerbation During Pregnancy and Breast-Feeding
JAMA 259:3441-3443, Nelson,L.M.,et al, 1988